The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Advances in first-line TKIs for advanced hepatocellular carcinoma
Markus Peck-Radosavljevic, MD, Medical University of Vienna, Vienna, Austria, notes that during the Phase IV STELLAR study (NCT04763408), tyrosine kinase inhibitors (TKIs) were the standard treatment for advanced or unresectable hepatocellular carcinoma (uHCC). However, first-line options have since shifted to immune-oncology (IO) agents or IO anti-angiogenic combinations. TKIs are now primarily used for patients with contraindications to first-line treatments or in second-line and later therapies. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
